Takeda, Frazier to launch HilleVax for norovirus vaccine development
Takeda Pharmaceutical has announced collaboration with Frazier Healthcare Partners to launch HilleVax to develop and commercialise the former’s clinical stage norovirus vaccine candidate, HIL-214 (formerly TAK-214). HIL-214 is